Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ordaos Bio
The biopharma industry may not have been the fastest adopter of artificial intelligence, but its vast potential means companies of every shape and size know they cannot ignore it. Executives, advisors and investors share their predictions around the impact of AI in 2023.
Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.
Emerging Company Profile: Mini-proteins offer some of the capabilities of small molecules and antibodies with fewer limitations, Ordaõs claims. The biotech wants to lead a paradigm shift from discovery to design.
- Artificial Intelligence
- Drug Discovery Technologies
- Large Molecule
- Other Names / Subsidiaries
- Ordaos Bio
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.